Table Graph
      published meta-analysis   sensitivity analysis   studies

vaccines in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias 6 months symptomatic COVIDdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.09 [0.07; 0.11] 0.09[0.07; 0.11]BNT162b2 phase 3 (C4591001, Polack), 202010%46,077NAnot evaluable confirmed Covid-19, from 1st dosedetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.18 [0.13; 0.25] COVE Moderna/NIH phase 3 (study 301), 2020 0.05 [0.03; 0.09] 0.10[0.03; 0.35]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020293%70,779moderatenot evaluable deathsdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.50 [0.09; 2.73] ChAdOx1 phase 3 (AstraZeneca), 2020 0.20 [0.02; 1.72] COVE Moderna/NIH phase 3 (study 301), 2020 0.50 [0.02; 14.84] ENSEMBLE (COV3001), 0 0.19 [0.04; 0.81] 0.28[0.11; 0.72]BNT162b2 phase 3 (C4591001, Polack), 2020, ChAdOx1 phase 3 (AstraZeneca), 2020, COVE Moderna/NIH phase 3 (study 301), 2020, ENSEMBLE (COV3001), 040%126,878moderatenot evaluable vaccine efficacy from randomization (ITT)detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.18 [0.13; 0.25] COVE Moderna/NIH phase 3 (study 301), 2020 0.07 [0.04; 0.11] 0.11[0.04; 0.29]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020291%71,720moderatenot evaluable confirmed COVID (any severity)detailed resultsC4591031- first boost, 2021 0.05 [0.02; 0.13] Novavax PREVEND-19 phase 3 US (2019nCoV-301), 2021 0.10 [0.05; 0.17] 0.08[0.05; 0.13]C4591031- first boost, 2021, Novavax PREVEND-19 phase 3 US (2019nCoV-301), 2021217%10,125lownot evaluable hospitalizationdetailed resultsENSEMBLE (COV3001), 0 0.18 [0.03; 1.17] 0.18[0.03; 1.17]ENSEMBLE (COV3001), 010%43,783NAnot evaluable symptomatic Covid-19detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.05 [0.02; 0.10] ChAdOx1 phase 3 (AstraZeneca), 2020 0.33 [0.26; 0.43] COVE Moderna/NIH phase 3 (study 301), 2020 0.06 [0.03; 0.11] ENSEMBLE (COV3001), 0 0.33 [0.27; 0.41] Hager (phase 3), 2022 0.31 [0.21; 0.44] Novavax phase 2 South Africa (2019nCoV-501), 2021 0.51 [0.27; 0.94] 0.20[0.12; 0.34]BNT162b2 phase 3 (C4591001, Polack), 2020, ChAdOx1 phase 3 (AstraZeneca), 2020, COVE Moderna/NIH phase 3 (study 301), 2020, ENSEMBLE (COV3001), 0, Hager (phase 3), 2022, Novavax phase 2 South Africa (2019nCoV-501), 2021691%123,649moderatenot evaluable 6 months severe COVID-19detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.03 [0.00; 0.46] 0.03[0.00; 0.46]BNT162b2 phase 3 (C4591001, Polack), 202010%NAnot evaluable asymptomatic COVID casedetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.33 [0.23; 0.48] 0.33[0.23; 0.48]ChAdOx1 phase 3 (AstraZeneca), 202010%11,636NAnot evaluable infection (PCR positive symptomatic or not)detailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.44 [0.33; 0.59] 0.44[0.33; 0.59]ChAdOx1 phase 3 (AstraZeneca), 202010%11,636NAnot evaluable severe COVID-19 (FDA definition)detailed resultsC4591031- first boost, 2021 0.25 [0.01; 5.50] 0.25[0.01; 5.50]C4591031- first boost, 202110%10,125NAnot evaluable severe COVID-19 occurrencedetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.25 [0.01; 5.62] C4591031- first boost, 2021 0.25 [0.01; 5.50] ChAdOx1 phase 3 (AstraZeneca), 2020 0.49 [0.02; 14.54] COVE Moderna/NIH phase 3 (study 301), 2020 0.02 [0.00; 0.27] ENSEMBLE (COV3001), 0 0.23 [0.11; 0.48] Hager (phase 3), 2022 0.17 [0.01; 3.33] Novavax phase 2 South Africa (2019nCoV-501), 2021 0.49 [0.02; 14.58] 0.21[0.11; 0.40]BNT162b2 phase 3 (C4591001, Polack), 2020, C4591031- first boost, 2021, ChAdOx1 phase 3 (AstraZeneca), 2020, COVE Moderna/NIH phase 3 (study 301), 2020, ENSEMBLE (COV3001), 0, Hager (phase 3), 2022, Novavax phase 2 South Africa (2019nCoV-501), 202170%170,533moderatenot evaluable vaccine efficacy after dose 1 (and before dose 2)detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.48 [0.32; 0.71] ChAdOx1 phase 3 (AstraZeneca), 2020 0.24 [0.14; 0.41] 0.35[0.18; 0.68]BNT162b2 phase 3 (C4591001, Polack), 2020, ChAdOx1 phase 3 (AstraZeneca), 2020275%61,849moderatenot evaluable related AE (TRAE)detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 4.91 [4.58; 5.26] 4.91[4.58; 5.26]BNT162b2 phase 3 (C4591001, Polack), 202010%43,252NAnot evaluable related SAE (TRSAE)detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 8.00 [0.42; 151.43] 8.00[0.42; 151.43]BNT162b2 phase 3 (C4591001, Polack), 202010%43,252NAnot evaluable serious adverse eventsdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 1.14 [0.88; 1.47] ChAdOx1 phase 3 (AstraZeneca), 2020 0.86 [0.64; 1.17] COVE Moderna/NIH phase 3 (study 301), 2020 1.04 [0.78; 1.40] 1.02[0.87; 1.20]BNT162b2 phase 3 (C4591001, Polack), 2020, ChAdOx1 phase 3 (AstraZeneca), 2020, COVE Moderna/NIH phase 3 (study 301), 202030%97,348moderatenot evaluable adverse eventsdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 2.62 [2.49; 2.76] COVE Moderna/NIH phase 3 (study 301), 2020 1.14 [1.08; 1.20] 1.73[0.77; 3.91]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 20202100%73,603moderatenot evaluable arrhythmiadetailed resultsC4591031- first boost, 2021 1.99 [0.07; 59.22] 1.99[0.07; 59.22]C4591031- first boost, 202110%10,075NAnot evaluable ATE (Myocardial infarction or ischemic stroke)detailed resultsENSEMBLE (COV3001), 0 0.50 [0.12; 2.00] 0.50[0.12; 2.00]ENSEMBLE (COV3001), 010%43,783NAnot evaluable deep vein thrombosisdetailed resultsENSEMBLE (COV3001), 0 3.00 [0.61; 14.86] 3.00[0.61; 14.86]ENSEMBLE (COV3001), 010%43,783NAnot evaluable Guillain-Barré syndrome detailed resultsENSEMBLE (COV3001), 0 1.00 [0.06; 15.98] 1.00[0.06; 15.98]ENSEMBLE (COV3001), 010%43,783NAnot evaluable hypertensiondetailed resultsC4591031- first boost, 2021 0.50 [0.02; 14.80] 0.50[0.02; 14.80]C4591031- first boost, 202110%10,075NAnot evaluable ischemic strokedetailed resultsENSEMBLE (COV3001), 0 0.67 [0.11; 3.99] 0.67[0.11; 3.99]ENSEMBLE (COV3001), 010%43,783NAnot evaluable life-threatening SAEdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.91 [0.51; 1.65] 0.91[0.51; 1.65]BNT162b2 phase 3 (C4591001, Polack), 202010%43,252NAnot evaluable Myocardial infarction detailed resultsC4591031- first boost, 2021 0.74 [0.17; 3.33] ENSEMBLE (COV3001), 0 1.00 [0.02; 50.39] 0.77[0.19; 3.13]C4591031- first boost, 2021, ENSEMBLE (COV3001), 020%53,858lownot evaluable pericarditis detailed resultsENSEMBLE (COV3001), 0 2.00 [0.07; 59.60] 2.00[0.07; 59.60]ENSEMBLE (COV3001), 010%43,783NAnot evaluable pulmonary embolismdetailed resultsC4591031- first boost, 2021 0.17 [0.01; 3.30] ENSEMBLE (COV3001), 0 4.00 [0.45; 35.79] 0.96[0.04; 21.48]C4591031- first boost, 2021, ENSEMBLE (COV3001), 0265%53,858moderatenot evaluable severe adverse eventsdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 1.74 [1.41; 2.14] 1.74[1.41; 2.14]BNT162b2 phase 3 (C4591001, Polack), 202010%43,252NAnot evaluable stroke (non-specific, hemorrhagic, and ischemic)detailed resultsC4591031- first boost, 2021 0.99 [0.06; 15.88] 0.99[0.06; 15.88]C4591031- first boost, 202110%10,075NAnot evaluable venous thromboembolism detailed resultsENSEMBLE (COV3001), 0 2.75 [0.88; 8.64] 2.75[0.88; 8.64]ENSEMBLE (COV3001), 010%43,783NAnot evaluable cerebral venous sinus thrombosis (CVST)detailed resultsC4591031- first boost, 2021 0.50 [0.02; 14.80] ENSEMBLE (COV3001), 0 2.00 [0.07; 59.60] 1.00[0.09; 10.99]C4591031- first boost, 2021, ENSEMBLE (COV3001), 020%53,858moderatenot evaluable appendicitisdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 2.00 [0.60; 6.65] C4591031- first boost, 2021 3.97 [0.18; 88.14] COVE Moderna/NIH phase 3 (study 301), 2020 0.67 [0.11; 3.99] ENSEMBLE (COV3001), 0 1.20 [0.37; 3.93] 1.41[0.67; 2.96]BNT162b2 phase 3 (C4591001, Polack), 2020, C4591031- first boost, 2021, COVE Moderna/NIH phase 3 (study 301), 2020, ENSEMBLE (COV3001), 040%127,657moderatenot evaluable arthralgia, grade 3-4detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 18.37 [13.54; 24.91] 18.37[13.54; 24.91]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable Bell's palsydetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 7.99 [0.42; 151.24] ChAdOx1 phase 3 (AstraZeneca), 2020 0.98 [0.20; 4.83] COVE Moderna/NIH phase 3 (study 301), 2020 3.00 [0.31; 28.83] ENSEMBLE (COV3001), 0 1.50 [0.25; 8.98] 1.76[0.65; 4.75]BNT162b2 phase 3 (C4591001, Polack), 2020, ChAdOx1 phase 3 (AstraZeneca), 2020, COVE Moderna/NIH phase 3 (study 301), 2020, ENSEMBLE (COV3001), 040%135,465moderatenot evaluable hypersensitivity, all termsdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 2.17 [0.82; 5.71] COVE Moderna/NIH phase 3 (study 301), 2020 1.41 [1.15; 1.72] 1.43[1.18; 1.74]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 202020%73,603moderatenot evaluable immediate allergic reactiondetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 1.00 [0.02; 50.42] ChAdOx1 phase 3 (AstraZeneca), 2020 1.95 [0.07; 58.15] 1.47[0.11; 19.07]BNT162b2 phase 3 (C4591001, Polack), 2020, ChAdOx1 phase 3 (AstraZeneca), 202020%67,193moderatenot evaluable lymphadenopathy, anydetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 10.69 [4.63; 24.69] 10.69[4.63; 24.69]BNT162b2 phase 3 (C4591001, Polack), 202010%37,586NAnot evaluable lymphadenopathy, grade 3-4detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 1.00 [0.06; 15.97] 1.00[0.06; 15.97]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable multiple sclerosisdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 1.95 [0.07; 58.15] 1.95[0.07; 58.15]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable musculoskeletal and connective tissue disorders, anydetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 3.65 [3.26; 4.09] COVE Moderna/NIH phase 3 (study 301), 2020 1.00 [0.06; 15.97] 3.64[3.25; 4.08]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 202020%67,937moderatenot evaluable myalgia, grade 3-4detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 27.64 [20.93; 36.50] 27.64[20.93; 36.50]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable myelitisdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 1.95 [0.18; 21.52] 1.95[0.18; 21.52]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable Potential Immune Gastrointestinal disordersdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.33 [0.03; 3.13] 0.33[0.03; 3.13]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable Potential Immune Musculoskeletal disordersdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.98 [0.06; 15.60] 0.98[0.06; 15.60]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable Potential Immune Neuroinflammatory disordersdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 1.22 [0.33; 4.54] 1.22[0.33; 4.54]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable Potential Immune Skin disordersdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.73 [0.16; 3.27] 0.73[0.16; 3.27]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable Potential Immune Vasculitidesdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.49 [0.02; 14.54] 0.49[0.02; 14.54]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable Thromboembolic eventsdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.49 [0.15; 1.62] 0.49[0.15; 1.62]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable fever, grade 3-4detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 43.29 [17.83; 105.10] 43.29[17.83; 105.10]COVE Moderna/NIH phase 3 (study 301), 202010%29,242NAnot evaluable local adverse reaction, any, dose 1detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 24.90 [22.13; 28.03] 24.90[22.13; 28.03]BNT162b2 phase 3 (C4591001, Polack), 202010%8,183NAnot evaluable local adverse reaction, any, dose 2detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 23.04 [20.30; 26.15] COVE Moderna/NIH phase 3 (study 301), 2020 33.74 [31.59; 36.03] 27.99[19.26; 40.68]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020296%36,742moderatenot evaluable local adverse reaction, grade 3-4, dose 2detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 15.04 [11.83; 19.12] 15.04[11.83; 19.12]COVE Moderna/NIH phase 3 (study 301), 202010%29,235NAnot evaluable systemic adverse reaction, any, dose 1detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 1.63 [1.50; 1.78] 1.63[1.50; 1.78]BNT162b2 phase 3 (C4591001, Polack), 202010%8,183NAnot evaluable systemic adverse reaction, any, dose 2detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 4.55 [4.13; 5.01] COVE Moderna/NIH phase 3 (study 301), 2020 6.69 [6.35; 7.05] 5.53[3.79; 8.06]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020298%36,749moderatenot evaluable systemic adverse reaction, grade 3-4, dose 2detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 9.50 [8.38; 10.77] 9.50[8.38; 10.77]COVE Moderna/NIH phase 3 (study 301), 202010%29,242NAnot evaluable0.0100.01.0relative treatment effectwww.metaEvidence.org2024-11-10 19:20 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons